Assenagon Asset Management S.A. Reduces $93M in Edwards Lifesciences Corporation ($EW)
Assenagon Asset Management reduced its stake in Edwards Lifesciences by 44.6% in the latest 13F filing.
Key Points
- Assenagon Asset Management cut its stake in Edwards Lifesciences by 44.6%, reducing its holdings by 1,020,584 shares to 1,265,714 shares, valued at $114.9 million.
- Edwards Lifesciences, trading at $90.78 on Saturday, has a market cap of $52.27 billion and a P/E ratio of 49.1.
- Analysts from RBC Capital, TD Cowen, and Barclays maintain buy ratings with targets up to $110, while insiders like CEO Bernard Zovighian sold shares recently.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Assenagon Asset Management S.A. has reduced its stake in Edwards Lifesciences Corporation (NYSE: EW) by 44.6%, according to its latest 13F filing with the SEC. The fund cut its holdings by 1,020,584 shares, leaving it with 1,265,714 shares valued at approximately $114.9 million as of the reporting period.
Assenagon Asset Management S.A. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
What Changed in Assenagon's Edwards Lifesciences Position
Assenagon trimmed its position in Edwards Lifesciences by 44.6%, reducing its shares from 2,286,298 to 1,265,714. The move decreased the value of its holdings to about $114.9 million.
Other Institutional Activity in Edwards Lifesciences
Several other major institutional investors also adjusted their positions in Edwards Lifesciences. BlackRock, Inc. added 129,018 shares, bringing its total to 52,590,933 shares valued at about $4.21 billion, marking a modest 0.2% increase. Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both opened new positions, acquiring 37,727,792 and 26,407,018 shares, respectively, valued at $3.02 billion and $2.11 billion. State Street Corp increased its holdings by 304,875 shares, a 1.2% boost, ending with 26,296,399 shares worth $2.11 billion. Meanwhile, JPMorgan Chase & Co reduced its position by 4,280,140 shares, a 16.4% decrease, leaving it with 21,744,712 shares valued at $1.73 billion.
Edwards Lifesciences Corporation Stock Up 0.6%
Shares of NYSE:EW traded near $90.78 on Saturday. Edwards Lifesciences has a market cap of about $52.27 billion and a P/E ratio of 49.1, with a forward P/E of 27.0. The stock's beta is 0.866, indicating lower volatility compared to the market. It has a 52-week range of $72.30 to $92.46, with a 50-day moving average of $84.29 and a 200-day moving average of $82.16. The company's current ratio stands at 4.42, and its quick ratio is 3.30, with a debt-to-equity ratio of 6.81.
$EW stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
In its most recent earnings report, Edwards Lifesciences posted revenue of approximately $6.30 billion, reflecting a 16.7% growth. The company achieved a net margin of 17.4% and a return on equity of 10.5%. Its earnings per share (EPS) stood at $1.85. The next earnings release is scheduled for July 23, 2026.
Insider Buying and Selling at Edwards Lifesciences Corporation
Recent insider activity at Edwards Lifesciences included several planned and unplanned sales. CEO Bernard Zovighian sold 523 shares at an average price of $87.92 on June 17, 2026, under a Rule 10b5-1 plan. SVP Andrew Dahl sold 568 shares at $86.08 on May 29, 2026, and CVP Donald Bobo Jr. sold 23,145 shares at $86.42 on May 27, 2026. CVP Daveen Chopra sold 1,500 shares at $84.60 on May 22, 2026, while CVP Daniel Lippis bought 620 shares at $72.68 on May 18, 2026.
Analysts Set New Price Targets
Analysts continue to show interest in Edwards Lifesciences. On June 16, 2026, RBC Capital reiterated its buy rating with a $100 price target. TD Cowen maintained a buy rating with a $104 target on June 2, 2026. Barclays also kept a buy rating, setting a $110 target on April 27, 2026. The consensus among 26 analysts is a buy recommendation, with an average price target of $96.92.
About Edwards Lifesciences
Edwards Lifesciences Corporation is a leading medical device company based in Irvine, California. It specializes in products for treating advanced cardiovascular diseases, including heart valve replacement and repair technologies. The company operates globally, providing innovative solutions under brands like Edwards SAPIEN, PASCAL, and EVOQUE. Led by CEO Bernard J. Zovighian, Edwards Lifesciences employs around 16,000 people worldwide.
Bottom Line
Assenagon's reduction in its holdings of Edwards Lifesciences reflects a significant shift in its investment strategy. Investors closely watch these filings to gauge institutional sentiment, though it's important to note that 13F filings are historical and may not represent current positions. Edwards Lifesciences remains a key player in the healthcare sector, with ongoing interest from both institutional investors and analysts.
Get Edwards Lifesciences Corporation alerts
New 13F filings, insider trades, and analyst moves on $EW, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.